272BIO Limited
Tom Hayward is an accomplished finance executive with extensive experience in the biotherapeutics and investment sectors. Currently serving as Chief Financial Officer at 272BIO Limited since June 2023, Tom previously held significant roles at finnCap Group, including Chief Operating Officer and Chief Financial Officer, where the focus was on providing growth services to dynamic companies. Additional leadership experience includes serving as Chief Financial Officer and Finance Director at Herald Investment Management Limited, Venture Capital Fund Manager at Schroders, and Corporate Finance Executive at KPMG. Tom holds a BA Hons in Psychology from the University of Cambridge and an MSc in Computing from Imperial College London.
This person is not in any teams
272BIO Limited
1 followers
272BIO Limited is an animal health antibody discovery company. Our strategy is to discover and develop highly innovative, afforable antibody therapeutics to treat companion animals and livestock. 272BIO Limited is a R&D company with run by a team of experienced antibody drug discovery experts looking to transform the animal health medicines market.